J Gynecol Oncol.  2013 Jan;24(1):83-91. 10.3802/jgo.2013.24.1.83.

Advanced ovarian cancer: what should be the standard of care?

Affiliations
  • 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA. bgoff@uw.edu

Abstract

The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an essential component in the treatment of ovarian cancer; however, the importance of surgical specialization and defining "optimal cytoreduction" as no visible residual disease has been further validated. Ongoing studies are defining the role of neoadjuvant chemotherapy in the upfront treatment of advanced ovarian cancer. In addition, clinical trials are evaluating intraperitoneal, dose dense, antiangiogenic drugs as well as targeted maintenance therapies which will establish new standards of care in the near future.

Keyword

Antiangiogenesis; Chemotherapy; Clinical trials; Dose dense chemotherapy; Intraperitoneal chemotherapy; Ovarian cancer; Surgery

MeSH Terms

Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Standard of Care
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr